News and Analysis
Endo bags Chapter 11 exit financing but questions linger over its future
- Sasha Padbidri
- +Bill Weisbrod
•2 min read
Specialty pharmaceutical company Endo raised $2.5bn of exit financing from the leveraged finance market this week as it prepares to emerge from bankruptcy later this month. But are LevFin investors sold on the resiliency of the reorganized business?